Akèy › Kansè (tout kalite) › Massachusetts
Etid klinik pou Kansè (tout kalite) nan Massachusetts
96 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05382559A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05874921A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07127874A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06881992A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT05920356A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Dana Farber Cancer Center ( Site 4013), Boston
Ap rekriteFaz 1/2
1 Month – 17 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT07630974A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Dana Farber/Harvard Cancer Center, Boston
- University of Massachusetts - UMass Chan Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06901531Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06910969Pan Tumor Rollover Study
- Dana_Farber Cancer Institute (DFCI), Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03899155Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07405164A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Dana-Farber Cancer Institute /ID# 279690, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07365241Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
- University of Massachusetts Memorial Medical Center, North Worcester
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Sep 18, 2026 · NCT03435796A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 3013), Boston
Ap rekriteFaz 1/2
1 Month – 17 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06941272Statins to Prevent Cancer Associated Blood Clots
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07303816Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Jiska laj 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06609473Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
- VA Boston Jamaica Plains Campus, West Roxbury
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05796375ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07232043RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Dana Farber Cancer Institute, Boston
- University of Massachusetts Chan Medical Center, Worcester
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06953960A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05123482A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05386108A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Dana Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06163534Lurbinectedin in FET-Fused Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 10 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05918640Prostate Active Surveillance Study
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
Ap rekriteEtid obsèvasyon
Laj 21 ak plis · Gason · Mizajou Sep 2, 2026 · NCT00756665A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
Ap rekriteFaz 1
Laj 18 a 99 · Tout sèks · Mizajou Sep 1, 2026 · NCT06983743A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07075185BRIDGE-SIC Efficacy Trial
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07735442Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- ak 1 plis
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Abatacept in Immune Checkpoint Inhibitor Myocarditis
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05335928A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06759649A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.